Business Context and Reporting Period
This Form 8-K Current Report was filed by ChromaDex Corporation (CDXC) on December 13, 2021. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and director compensation arrangements.
Material Changes
- Board Expansion: The Board size increased from eight to nine members.
- Director Appointment: Gary Ng was appointed as a director effective December 13, 2021, serving until the 2022 annual meeting.
- Director Resignation: Tony Lau resigned from the Board effective November 2, 2021. Mr. Ng replaces Mr. Lau as the director nominated by Champion River Ventures Limited.
- Committee Assignment: Mr. Ng was appointed to the Compensation Committee and is deemed an independent director under Nasdaq listing standards.
Compensation and Outlook
Management commentary is limited to the background of the new director and the terms of his appointment. No financial guidance, outlook, or discussion of risks and contingencies is included in this filing.
Compensation Arrangements for Gary Ng:
- Annual Retainer: $40,000 for Board service.
- Committee Fee: $7,500 per year for Compensation Committee service.
- Initial Stock Option: 40,000 shares granted on December 13, 2021, vesting in equal annual installments over three years.
- Annual Stock Option: 20,000 shares to be granted at each annual meeting, vesting over one year.
- Exercise Price: Equal to the fair market value of common stock on the grant date.
Investor Verification Checklist
- Verify the current Board composition and independence status on the Nasdaq Capital Market.
- Confirm the vesting schedule and exercise price of the 40,000 shares granted to Gary Ng.
- Review the relationship between Champion River Ventures Limited, Horizon Ventures Limited, and the new director to understand potential conflicts of interest.
- Check subsequent filings for the impact of this governance change on the Compensation Committee's decisions.